Serum anti‑TSTD2 antibody as a biomarker for atherosclerosis‑induced ischemic stroke and chronic kidney disease

Masaaki Kubota; Bo-Shi Zhang; Shu-Yang Li; Yoichi Yoshida; Hao Wang; Akihiko Adachi; Tomoo Matsutani; Seiichiro Mine; Toshio Machida; Ikuo Kamitsukasa; Takeshi Wada; Akiyo Aotsuka; Kenichiro Kitamura; Hirotaka Takizawa; Hideyuki Kuroda; Yasuo Iwadate; Takaki Hiwasa

doi:10.3892/mi.2022.64

Serum anti‑TSTD2 antibody as a biomarker for atherosclerosis‑induced ischemic stroke and chronic kidney disease

Med Int (Lond). 2022 Dec 21;3(1):4. doi: 10.3892/mi.2022.64. eCollection 2023 Jan-Feb.

Authors

Masaaki Kubota¹, Bo-Shi Zhang¹, Shu-Yang Li¹, Yoichi Yoshida^{1

2}, Hao Wang^{1

3}, Akihiko Adachi¹, Tomoo Matsutani¹, Seiichiro Mine^{1

4

5}, Toshio Machida^{1

5

6}, Ikuo Kamitsukasa^{7

8}, Takeshi Wada⁹, Akiyo Aotsuka⁹, Kenichiro Kitamura¹⁰, Hirotaka Takizawa¹¹, Hideyuki Kuroda¹², Yasuo Iwadate^{1

2}, Takaki Hiwasa^{1

2}

Affiliations

¹ Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
² Comprehensive Stroke Center, Chiba University Hospital, Chiba 260-8677, Japan.
³ Department of Anesthesiology, Stroke Center, The First Affiliated Hospital and Health Science Center, Jinan University, Guangzhou, Guangdong 510630, P.R. China.
⁴ Department of Neurological Surgery, Chiba Prefectural Sawara Hospital, Chiba 287-0003, Japan.
⁵ Department of Neurological Surgery, Chiba Cerebral and Cardiovascular Center, Chiba 290-0512, Japan.
⁶ Department of Neurosurgery, Eastern Chiba Medical Center, Chiba 283-8686, Japan.
⁷ Department of Neurology, Chiba Rosai Hospital, Chiba 290-0003, Japan.
⁸ Department of Neurology, Chibaken Saiseikai Narashino Hospital, Chiba 275-8580, Japan.
⁹ Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba 260-0852, Japan.
¹⁰ Kitakurihama Takuchi Clinic, Yokosuka, Kanagawa 239-0807, Japan.
¹¹ Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260-0025, Japan.
¹² Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama 340-0203, Japan.

Abstract

Autoantibodies can be used in the early diagnosis and treatment of atherosclerosis-related diseases. Using ProtoArray^® screening of samples from patients with atherosclerosis, the present study identified thiosulfate sulfurtransferase-like domain-containing 2 (TSTD2) as a novel atherosclerosis antigen. The serum TSTD2 antibody levels were then quantified using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay. This demonstrated the levels of TSTD2 antibodies (TSTD2-Abs) to be significantly higher in patients with acute cerebral infarction or chronic kidney disease than in healthy donors. The TSTD2-Ab levels were also found to be higher in males, older adults, smokers, in those who consumed alcohol regularly, and in those with hypertension. Furthermore, Spearman's rank correlation analysis revealed TSTD2-Ab levels to be strongly associated with measures of atherosclerosis severity, including plaque scores, intima-media thickness of the carotid artery and the cardio-ankle vascular index. Thus, TSTD2-Abs may thus be a promising novel biomarker for atherosclerosis-related cerebral infarction and kidney disease.

Keywords: acute cerebral infarction; atherosclerosis; autoantibody; chronic kidney disease; thiosulfate sulfurtransferase-like domain-containing 2.

Associated data

figshare/10.6084/m9.figshare.21510009.v1

Grants and funding

Funding: The present study was supported, in part, by research grants from the Japan Science and Technology Agency (Exploratory Research No. 14657335) and JSPS KAKENHI (grant nos. 20K17953, 22K09227, 17K16626, 22K07273 and 19K09451).